Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) Lymphoma
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to evaluate whether a Rituximab plus 2 CdA combination therapy
is effective and safe in the treatment of patients with advanced or relapsed lymphoma of the
mucosa associated lymphoid tissue (MALT).